Improving nutritional status and pill burden in patients with pancreatic diseases

Dr. Westphal and Mr. Aldrich founded Alnara Pharmaceuticals, Inc. in 2008 with Alexey Margolin to develop non-systemic protein therapeutics. Shortly thereafter, Alnara obtained exclusive worldwide rights to develop, manufacture, and market liprotamase, a unique pancreatic enzyme replacement therapy to treat patients with cystic fibrosis. Alnara was developing the drug in conjunction with the Cystic Fibrosis Foundation. Mr. Aldrich served as chair of the board and Dr. Westphal served on the board. Alnara was sold to Eli Lilly in July of 2010, approximately six months after Longwood I invested.